Medpace Holdings, Inc. reports developments in its global, full-service clinical contract research organization business, providing Phase I-IV clinical development services to biotechnology, pharmaceutical and medical device companies. Company news centers on quarterly and annual operating results, conference-call announcements and performance measures used in the CRO model, including revenue, EBITDA, backlog conversion, net new business awards and book-to-bill ratios.
Updates also describe Medpace's therapeutic and regulatory expertise across major development areas such as oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective programs.
Medpace Holdings, Inc. (MEDP) reported a revenue increase of 18.8% to $308.6 million for Q4 2021, compared to $259.7 million in Q4 2020. For the full year 2021, revenue rose 23.4% to $1,142.4 million. The company secured $458.7 million in net new business awards for Q4 2021, up 27.9%, leading to a book-to-bill ratio of 1.49x. However, Q4 GAAP net income decreased slightly to $50.0 million from $50.9 million in the previous year. Full-year net income was $181.8 million. Medpace forecasts 2022 revenue between $1.400 billion and $1.460 billion.
Medpace Holdings, Inc. (Nasdaq: MEDP) will release its fourth quarter and fiscal year 2021 financial results after market close on February 14, 2022. A conference call is scheduled for February 15, 2022, at 9:00 a.m. ET to discuss the results. Interested parties can participate by dialing 800-219-7113 (domestic) or 574-990-1030 (international) using passcode 9164466. The call will be accessible via webcast on the company's website, with a replay available until February 22, 2022.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a 28.3% increase in revenue for Q3 2021, reaching $295.6 million, compared to $230.4 million in Q3 2020. Net new business awards also rose by 29.4% to $408.0 million, leading to a net book-to-bill ratio of 1.38x. GAAP net income was $48.6 million, or $1.29 per diluted share, reflecting a net income margin of 16.4%. The company forecasts 2021 revenue of $1.135 billion to $1.145 billion and 2022 revenue of $1.400 billion to $1.460 billion.
Medpace Holdings, Inc. (NASDAQ: MEDP) announced it will report its third quarter 2021 financial results after market close on October 25, 2021. A conference call to discuss these results is scheduled for October 26, 2021, at 9:00 a.m. ET. Participants can join by dialing 800-219-7113 (domestic) or 574-990-1030 (international) using passcode 5177474. The call will also be accessible via webcast on Medpace's investor website, with a replay available until November 2, 2021.
Medpace Holdings (Nasdaq: MEDP) will present at Baird’s Global Healthcare Conference on September 14, 2021, at 8:30 a.m. ET. The presentation will feature Jesse Geiger, President, and Kevin Brady, CFO. A live webcast will be available on the company’s website with replay options following the event.
Medpace is a global clinical contract research organization providing comprehensive clinical development services across various therapeutic areas, employing around 4,100 people in 40 countries.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a 35.8% increase in revenue for Q2 2021, reaching $278.3 million. The company's backlog grew 29.8% to $1.7 billion, and net new business awards hit $387.6 million, yielding a book-to-bill ratio of 1.39x. GAAP net income rose to $39.9 million or $1.06 per diluted share, representing a net income margin of 14.3%. The company forecasts 2021 revenue between $1.110 billion and $1.150 billion and GAAP net income between $162.5 million and $169.5 million.
Medpace Holdings, Inc. (Nasdaq: MEDP) announced the appointments of Jesse Geiger as president and Kevin Brady as chief financial officer, effective August 1, 2021. Geiger, who has been with Medpace since 2007 and previously served as CFO, will focus on driving growth while maintaining strategic oversight. Brady, appointed CFO, has been the executive director of finance since 2018. Both appointments aim to strengthen leadership as Medpace accelerates the global development of medical therapeutics.
Medpace Holdings, Inc. (Nasdaq: MEDP) will announce its second quarter 2021 financial results on July 26, 2021, after market close. A conference call is scheduled for the following morning, July 27, 2021, at 9:00 a.m. ET to discuss the results. Participants can join by dialing 800-219-7113 (U.S.) or 574-990-1030 (international) with passcode 4092073. Webcast access will be available on the Company’s website, where a replay will also be provided. Medpace is a global clinical contract research organization focused on accelerating medical therapeutic development.
Medpace Holdings, Inc. (Nasdaq: MEDP) has announced its participation in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 9:00 a.m. ET. The event will feature key executives including August Troendle, President & CEO, and Jesse Geiger, CFO & COO. Investors can access the live webcast through the company’s website, with a replay available post-event. Medpace specializes in full-service clinical contract research, focusing on accelerating the development of safe medical therapeutics in various therapeutic areas.
Medpace Holdings, Inc. (Nasdaq: MEDP) reported a significant growth in its first quarter 2021 financial results, with revenue rising 12.6% to $260.0 million, up from $230.9 million in Q1 2020. The company achieved a backlog increase of 26.1%, reaching $1.6 billion, and net new business awards totaled $356.2 million, leading to a robust book-to-bill ratio of 1.37x. GAAP net income surged 49.1% to $43.3 million, or $1.14 per diluted share, while EBITDA rose 32.1% to $53.6 million. Medpace also forecasts a revenue increase for 2021 between $1.090 billion and $1.150 billion.